Jose Enrique M. R.
- Country
- Spain
- Department
- Neurology
Research Overview
- Phase 3 Randomized Double‑Blind Study of Orelabrutinib vs Placebo on Disability Progression in Non‑Active Secondary Progressive Multiple Sclerosis
- Phase 3 Randomized, Double-Blind Study of Frexalimab (SAR441344) Versus Teriflunomide in Adults with Relapsing Multiple Sclerosis
- A Randomized, Double-Blind, Parallel-Group Study Comparing Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis Patients, with Open-Label Remibrutinib Extension
Data & Insights
Has run more than one trial at 126 of 308 partner sites.
Specializations
Multiple Sclerosis Treatment
This investigator specializes in the research and treatment of multiple sclerosis (MS), with particular emphasis on both relapsing and nonrelapsing secondary progressive forms of the condition.
- Relapsing MS Management
- Secondary Progressive MS Treatment
- Novel Therapeutic Approaches
The investigator's work encompasses evaluation of innovative therapeutic agents for MS treatment.
Neurological Innovation
The investigator focuses on central nervous system inflammation and its treatment through various therapeutic approaches, including both monotherapy and combination therapy strategies.
- Brain Inflammation Research
- Combination Therapy Assessment
- MRI-based Disease Monitoring
Their research includes advanced imaging techniques to monitor treatment effectiveness in neurological conditions.
Disease Progression Studies
The investigator's research encompasses studies on disability progression in multiple sclerosis, with particular attention to comparative therapeutic effectiveness.
- Disability Assessment Methods
- Disease Progression Markers
- Treatment Response Evaluation
Their work includes assessment of therapeutic interventions aimed at slowing disease advancement.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.